Regeneron Pharmaceuticals said it plans to eliminate some jobs as it restructures its partnership with Sanofi, reported Bloomberg.
"We will be reducing the size of our commercial and medical affairs teams related to the Kevzara and Praluent restructuring," a Regeneron spokeswoman said.
She added "we are currently talking to impacted teams and individuals and they will be given the opportunity to apply for other open roles where possible."
Specifically, Regeneron said there will be no roles at the company for the rheumatoid arthritis drug Kevzara, which Sanofi is expected to gain global rights to under the restructuring.
In regards to Praluent, Regeneron is cutting 15 field and supporting staff in New York in mid-February as part of the restructuring.
Regeneron staff across the country may also be affected, though the company declined to comment further because it said it is still finalizing specifics.
To read more NewsPoints articles, click here.